Reviewer's report

Title: Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells

Version: 3 Date: 30 August 2012

Reviewer: Davidson D Ateh

Reviewer's report:

The revised manuscript is satisfactory and I recommend publication.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I am a founder, shareholder and Director of BioMoti Limited, a UK based start-up company that develops targeted drug delivery platforms for cancer indications. I do not believe there are direct or tangible benefits with respect to the findings presented in this reviewed paper but the paper does support the use of nanoparticles as many others in the field.